Results 231 to 240 of about 26,068 (276)

Efficacy and safety of mineralocorticoid receptor antagonists for the treatment of low-renin hypertension: a systematic review and meta-analysis. [PDF]

J Hum Hypertens
Shah SS, Zhang J, Gwini SM, Young MJ, Fuller PJ, Yang J.   +5 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mineralocorticoid receptor antagonists

2023
Abstract Hypertension, post-myocardial infarction, and heart failure are the cardiovascular clinical syndromes where mineralocorticoid receptor antagonists (MRAs) have shown a beneficial effect. Most guidelines, while recommending MRAs, do not make a clear recommendation as to which MRAs should be used, how doses should be titrated, or ...
Bertram Pitt, João Pedro Ferreira, Faiez Zannad   +2 more
openaire   +1 more source

Mineralocorticoid Receptor Blockers: Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonists

Current Hypertension Reports, 2020
Recently, nonsteroidal mineralocorticoid receptor (MR) antagonists (MRAs), which have been proposed to be called MR blockers (MRBs), have become available for clinical use, but their clinical role is unknown. We reviewed the clinical roles of MRAs and MRBs based on previous knowledge and as demonstrated in representative clinical trials.Steroidal MRAs,
Daisuke, Sueta, Eiichiro, Yamamoto, Kenichi, Tsujita   +2 more
openaire   +2 more sources

Mineralocorticoid receptor antagonists

Current Hypertension Reports, 2007
With an increasingly aging population, the need for effective treatment of cardiovascular diseases (eg, heart failure, hypertension, and ischemic heart disease) cannot be overemphasized. The vital importance of mineralocorticoid receptor antagonists for treating cardiovascular conditions has only been appreciated in the last decade. The re-emergence of
Parthasarathy, Hari Krishnan, MacDonald, Thomas M.   +1 more
openaire   +3 more sources

Mineralocorticoid receptor antagonists

2022
Abstract This chapter studies the use of aldosterone antagonists, also known as mineralocorticoid receptor antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction—now called heart failure with reduced ejection fraction (HFrEF)—have been very ...
S. Rekhraj, Ben. R. Szwejkowski, Allan D. Struthers   +2 more
openaire   +1 more source

3,3-Bisaryloxindoles as mineralocorticoid receptor antagonists

Bioorganic & Medicinal Chemistry Letters, 2005
Syntheses and SAR studies of 3,3-bisaryloxindole analogues provided potent mineralocorticoid receptor (MR) antagonists that were selective over other steroid nuclear hormone receptors.
David A, Neel, Matthew L, Brown, Peter A, Lander, Timothy A, Grese, Jean M, Defauw, Robert A, Doti, Todd, Fields, Sally Ann, Kelley, Stephon, Smith, Karen M, Zimmerman, Mitchell I, Steinberg, Prabhakar K, Jadhav   +11 more
openaire   +3 more sources

Mineralocorticoid Receptor Antagonists in Primary Aldosteronism

Current Pharmaceutical Design, 2019
Background:Primary aldosteronism is the most common causes of secondary hypertension. Patients suffering from this clinical syndrome have an increased cardiovascular risk and target organ damage. Mineralocorticoid receptor antagonists are the optimal pharmaceutical option for the management of such patients.Objectives:The study aimed to assess the ...
Konstantinos, Stavropoulos, Christodoulos, Papadopoulos, Konstantinos, Koutsampasopoulos, Georgios, Lales, Christos, Mitas, Michael, Doumas   +5 more
openaire   +2 more sources

Nonsteroidal antagonists of the mineralocorticoid receptor

Current Opinion in Nephrology and Hypertension, 2015
The broad clinical use of steroidal mineralocorticoid receptor antagonists (MRAs) is limited by the potential risk of inducing hyperkalemia when given on top of renin-angiotensin system blockade. Drug discovery campaigns have been launched aiming for the identification of nonsteroidal MRAs with an improved safety profile.
Peter, Kolkhof, Christina, Nowack, Frank, Eitner   +2 more
openaire   +2 more sources

Non-steroidal mineralocorticoid receptor antagonists

Expert Opinion on Therapeutic Patents, 2007
The mineralocorticoid hormone aldosterone is essential in regulating the body’s salt and water balance. However, abnormal activation of the mineralocorticoid receptor (MR) by elevated levels of aldosterone and salt imbalance cause hypertension and other effects detrimental to the cardiovascular system. Thus, MR antagonists are expected to be beneficial
Marvin J Meyers, Xiao Hu
openaire   +1 more source